Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Absci CorporationABSI-3.88133.442.21-3.99-42.24%-24.81%25.09$4.10$10.8137,920$3.84

Detail of Absci Corporation

 
CEO
Mr. Sean McClain
Employees
155
Industry
Biotechnology
Sector
Healthcare
Market cap
$434M

Company details

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; and with AstraZeneca PLC for AI-driven drug discovery against an oncology target. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Revenue
Revenue (Rev)
$3.25M
Absci Corporation
ABSI • XNGS • US
$3.84
+2.52 (190.91%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.99
Margin profit
0.00%
52 week low
$1.26
52 week high
$6.585
50-day simple moving average
$4.12
200-day simple moving average
$4.10
Percent held by insiders
20.32%
Percent held by institutions
61.12%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ABSI +172.34%
eps change
ABSI 0.00%